News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Maxygen, Inc. Says Drug Under Amgen Patent Cloud
June 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BANGALORE, June 13 (Reuters) - Shares of biotechnology firm Maxygen Inc slid as much as 30 percent after news that it could face a legal patent battle with sector leader Amgen Inc over its lead cancer drug.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Amgen
MORE ON THIS TOPIC
Job Trends
Takeda cuts send layoffs soaring in May, rising year over year
May 19, 2026
·
4 min read
·
Angela Gabriel
Weight loss
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
May 7, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly investing billions to prepare for overseas oral GLP-1 launches
April 14, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns
April 13, 2026
·
2 min read
·
Nick Paul Taylor
